| PEXIDARTINIB HYDROCHLORIDE | None | ||
| 200MG, 125MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| TURALIO is a kinase inhibitor indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. | |||
|
Yes
| |||
| TURALIO | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||
| ********* ********** *-*** ***/** *-*** ******** *** **** ******** | ********* ********** *-*** ***/** *-*** ******** *** **** ******** | ********* ********** *-*** ***/** *-*** ******** | ********* ********** *-*** ***/** *-*** ******** *** **** ******** | ********* ********** *-*** ***/** *-*** ******** *** **** ******** | ****** **********, *** *********** ******** | ***** ***** ** * ******** ********** ******* | ***** ***** ** * ******** ********** ******* | ************ ** * ******** ********** ******* | ********* ** * ******** **** ********* ******* | ************ ** * ******** ********** ******* | ************ ** * ******** ********** ******* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|